AI assistant
IMPEDIMED LIMITED — Capital/Financing Update 2017
Apr 23, 2017
65135_rns_2017-04-23_e51808c9-d363-4d21-a443-a986b6604058.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [226 x 43] intentionally omitted <==
24 April 2017
ASX ANNOUNCEMENT
ImpediMed Quarterly Results and Investor Conference Call
Brisbane, Australia - ImpediMed Limited (ASX: IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending March 31, 2017 on Wednesday April 26, 2017.
Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at 9.15am AEST on Wednesday April 26, 2017.
To pre-register please follow this link: https://services.choruscall.com.au/diamondpass/impedimed-138746-invite.html
You will receive a calendar notification with dial in details and a PIN for fast track access to the call.
For further information please contact:
Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100
Media and Investor Contacts:
In Australia:
Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.